IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

PANASCI ET AL.

Examiner: James D. Anderson

APPLICATION NO: 10/534,573

FILED: MAY 11, 2005

FOR: COMBINATION OF A NITROGEN MUSTARD ANALOGUE AND

IMATINIB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC

LEUKEMIA

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

PETITION FOR EXTENSION OF TIME

Sir:

The Office Action of July 29, 2008 has a shortened statutory time set to expire on October 29, 2008. A three-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1110 for payment of the extension fee. An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis Pharmaceuticals Corp. Patents Pharma One Health Plaza, Building 101 East Hanover, NJ 07936-1080

Date:

1/24/09

George R. Dohmann Attorney for Applicants

Reg. No. 33,593

Phone No. (862) 778-7824